Ignyta Investor Information

Ignyta, Inc. is writing a new story for cancer treatment, a story that features our distinctive Rx/Dx strategy to blaze a new path forward for patients.

Physicians discussing a patient chart

Our integrated approach combines precision therapeutics with companion molecular diagnostics for the potential benefit of patients with cancer.

Our people work daily to develop meaningful new drugs that target the molecular abnormalities of cancer, allowing us to advance precision therapies to treat each patient’s specific cancer.

We endeavor to eradicate residual disease in precisely defined patient populations by 2030, an audacious goal – backed by the unique combination of delivering the next generation of targeted therapeutics, accompanied by highly informative biomarkers for patient selection, treatment, and monitoring – that makes us confident we can help write the next chapter in the ever-changing story of cancer care.

To stay up to date on all Ignyta investor information, including Press Releases, Stock Information, SEC filings, and more, sign up for Ignyta email alerts.

Ignyta, Inc. (Nasdaq: RXDX) stock information, including a current stock ticker and historical trending.

View Stock Info

A sortable database of downloadable Ignyta, Inc. Press Releases from 2012 to present in PDF format.

Read Press Releases

A sortable database of Ignyta, Inc. SEC filings for all years 2013 to present, in HTML, PDF, and XLS formats.

View SEC Filings

Ignyta Events & Presentations

As a leader in biotechnology and precision medicine, the Ignyta team frequently presents at industry conferences and events, including clinical data, information on Ignyta clinical trials, and breakthroughs in the evolution of cancer treatment.

View Upcoming Events
Speaker in front of large group of people

Stock Information

Table scrolls to the right >>

9.15
current stock price
4 PM ET | Feb 27, 2017
Previous Close 9.15 Day High 0.00
Open 0.00 Day Low 0.00
Volume 0 52-Week High 9.70
Exchange NASDAQ 52-Week Low 4.15

Press Releases

Feb 09, 2017 Ignyta's Updated Phase 1 Data on Safety, Anti-Tumor Activity and CNS Activity of Entrectinib in Cancers with TRK, ROS1 or ALK Fusions Published in Cancer Discovery
Largest published safety experience of any TRK inhibitor in clinical development showed entrectinib continues to be well tolerated As of September 2016 data cutoff, RECIST responses were noted in 3 of 3 patients with TRK-positive extracranial solid tumors,
Feb 08, 2017 Ignyta to Present at the LEERINK Partners 6th Annual Global Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, announced today that Jacob Chacko, M.D., its Chief Financial Officer, will make a presentation at the LEERINK Partners 6th Annual Global Healthcar
Jan 04, 2017 Ignyta to Present at 35th Annual J.P. Morgan Healthcare Conference
SAN DIEGO--(BUSINESS WIRE)-- Ignyta, Inc. (Nasdaq: RXDX), a biotechnology company focused on precision medicine in oncology, announced today that Jonathan Lim, M.D., its Chairman and Chief Executive Officer, will make a presentation at the 35th Annual J.P. Morgan Healthc